Ceftobiprole medocaril for the treatment of community-acquired pneumonia
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2018.1516749
Abstract: ABSTRACT Introduction: Ceftobiprole is a novel broad-spectrum cephalosporin with excellent activity against a broad range of pathogens that are important in community-acquired pneumonia (CAP), including drug-resistant pneumococci, methicillin-resistant Staphylococcus aureus, and Pseudomonas aeruginosa. Areas covered:… read more here.
Keywords: ceftobiprole medocaril; treatment; community acquired; cap ... See more keywords
Ceftobiprole medocaril for the treatment of pneumonia
Sign Up to like & getrecommendations! Published in 2023 at "Expert Review of Anti-infective Therapy"
DOI: 10.1080/14787210.2023.2202851
Abstract: ABSTRACT Introduction Ceftobiprole, a fifth-generation cephalosporin, exhibits a broad-spectrum activity against common pathogens causing pneumonia, including multidrug-resistant organisms (MDROs), such as penicillin-resistant S. pneumoniae (PRSP) and methicillin-resistant Staphylococcus aureus (MRSA) and non-extended-spectrum β -lactamase (non-ESBL)… read more here.
Keywords: ceftobiprole medocaril; medocaril treatment; pneumonia; treatment pneumonia ... See more keywords